Despite global uncertainty, we remain committed to uniting this dedicated community and streamlining the progression of RAS targeted therapeutics. In September we saw expert insights and latest data exploring novel discoveries, identify rational anti-RAS combination strategies & accelerate the translation of next generation mutant-targeted RAS therapies into human clinical trials.

As the first KRAS inhibitors reach the clinic and show promising opportunities to address unmet clinical need, the 2nd RAS Targeted Drug Development Summit 2020 deep dived into how we can advance the clinical translation of first-generation anti-RAS therapies.

This two-track meeting truly was the most comprehensive and definitive platform, dedicated to virtually uniting the largest community of RAS experts from large pharma, innovative biotech and research institutes to capitalize on the emerging therapeutic opportunities to finally bring an end to RAS driven cancers.